en.Wedoany.com Reported, Roche recently launched the cobas MPX-E donor screening assay in Europe. This is a qualitative in vitro diagnostic test for the detection and differentiation of Human Immunodeficiency Virus (HIV-1 and HIV-2) as well as Hepatitis B Virus, Hepatitis C Virus, and Hepatitis E Virus.
The new assay is now available in countries accepting the CE mark. It aims to enhance blood safety by integrating screening for multiple pathogens. It consolidates the detection of four viral targets into a single workflow, helping laboratories streamline their processes.
The cobas MPX-E assay is designed to meet current laboratory needs, improving detection sensitivity and specificity. It performs particularly well in preventing the transmission of Hepatitis E Virus through blood transfusions. Additional features include dual-target detection for HIV-1 Group M, targeting two independent regions of the viral genome. This approach enhances test reliability and maintains accuracy even when the viral genome mutates.
As a multiplex real-time PCR test, cobas MPX-E can simultaneously detect and differentiate HIV, HBV, HCV, and HEV. Laboratories can choose flexible testing options as needed, screening for all four pathogens or individual ones. The new assay runs on the cobas x800 systems, which are already used globally for over ten million tests per month.
For laboratories already screening for HEV, this assay shortens the result turnaround time. For laboratories planning to implement HEV screening, cobas MPX-E provides a cost-effective solution without requiring additional space or hardware. Matt Sause, CEO of Roche Diagnostics, stated, "Safe and timely access to blood products is a cornerstone of modern healthcare. With the launch of the cobas MPX-E test, we are helping to ensure patients receive the safe blood products they need by providing a fully integrated solution that includes the most critical viral pathogens and improves laboratory efficiency."
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
